GlassScriptPhysician profile
Megan B Bender
NPI 1639506348
$10,156.22
in general payments reported to CMS, 2019-2025
32 companies · $3,418 in 2025
The $3,418 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $890 · 2022: $750 · 2023: $1,956 · 2024: $3,144 · 2025: $3,418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,322 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,321.84 |
| Education | $195.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,758.58 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $1,071.63 | 2022-2025 | Ilumya, Absorica Ld, Winlevi |
| Genzyme Corporation | $1,007.32 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $790.76 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $615.97 | 2021-2025 | Tremfya, Stelara, Simponi |
| Ucb, INC. | $608.50 | 2023-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $547.50 | 2022-2025 | |
| Pfizer INC. | $414.70 | 2021-2025 | |
| Incyte Corporation | $405.04 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $367.08 | 2023-2024 | Sotyktu |
| Leo Pharma INC. | $316.87 | 2023-2025 | Adbry, Anzupgo, Spevigo |
| Amgen INC. | $286.10 | 2022-2025 | Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.11 | 2023-2025 | Spevigo |
| Lilly USA, LLC | $266.21 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Scientific Affairs, LLC | $265.82 | 2021-2025 | Tremfya |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $187.18 | 2023-2025 | Nemluvio, Oracea, Epsolay |
| Arcutis Biotherapeutics, INC. | $156.93 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $154.81 | 2023-2024 | Vtama |
| Mayne Pharma Commercial LLC | $124.93 | 2023-2025 | |
| Genentech USA, INC. | $88.07 | 2021 | |
| Organon LLC | $71.51 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $54.17 | 2024-2025 | Cabtreo, Siliq |
| Almirall LLC | $50.55 | 2025 | Seysara, Klisyri |
| Organogenesis INC. | $50.34 | 2024 | Affinity |
| Verrica Pharmaceuticals INC. | $48.96 | 2023-2024 | Ycanth |
| Botanix Sb INC | $46.42 | 2025 | Sofdra |
| Krystal Biotech INC | $41.35 | 2024 | Vyjuvek |
| Vyne Pharmaceuticals INC. | $21.80 | 2021 | |
| Biofrontera INC. | $19.60 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Journey Medical Corporation | $19.47 | 2025 | |
| Lnhc, INC | $16.00 | 2025 | Zelsuvmi |
| Boston Scientific Corporation | $12.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Bender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.